Two months after the FDA issued a safety alert on Pfizer's Chantix, the company in January agreed to update labeling to warn patients about the potential for serious neuropsychiatric symptoms.
Two months after the FDA issued a safety alert on Pfizer’sChantix, the company in January agreed to update labeling to warn patientsabout the potential for serious neuropsychiatric symptoms.
From the March 01, 2008 Issue of MM+M - Medical Marketing and Media
Get the most out of 
Register for free and enjoy unlimited access to:
